December 2024 in “Frontiers in Endocrinology” This research reviewed existing literature to explore treatment options for androgen-dependent diseases, reporting that among prostate cancer therapies analyzed, the drug olaparib as monotherapy resulted in longer survival compared to the combination of apalutamide and abiraterone, though combined treatment efficacy differences were not statistically significant.
November 2021 in “Pharmaceutical Sciences” This study found that the compound androstane-17-carboxamide 6 may serve as a lead for new drugs to treat BPH and prostate cancer by reducing the weight of androgen-dependent glands.
September 2020 in “Current Enzyme Inhibition” In this study, researchers found that steroidal 17β-carboxamides 1-4 significantly inhibited 5α-reductase enzyme activity and reduced prostate weight more effectively than finasteride in a hamster model, without toxic side effects, suggesting potential for treating benign prostatic hyperplasia.
147 citations
,
April 1990 in “The Journal of Clinical Endocrinology and Metabolism” This study found that finasteride significantly suppresses serum dihydrotestosterone levels at all tested doses in normal male volunteers without significant adverse effects.
11 citations
,
March 2014 in “Journal of The European Academy of Dermatology and Venereology” In this study, researchers found that androgen receptor gene polymorphism is associated with higher androgenetic alopecia grades and PSA levels in men with benign prostatic hyperplasia, but not with prostate cancer.